Review
Version 1
Preserved in Portico This version is not peer-reviewed
Milestones in Antiviral Drug Development
Version 1
: Received: 4 December 2023 / Approved: 5 December 2023 / Online: 5 December 2023 (14:46:01 CET)
A peer-reviewed article of this Preprint also exists.
De Clercq, E. Selected Milestones in Antiviral Drug Development. Viruses 2024, 16, 169. De Clercq, E. Selected Milestones in Antiviral Drug Development. Viruses 2024, 16, 169.
Abstract
In this review article will be described the (wide) variety of approaches that I envisaged to develop a specific therapy of viral infections: (i) interferon and its inducers, (ii) HSV, VZV and CMV inhibitors, (iii) NRTIs (nucleoside reverse transcriptase inhibitors), NtRTIs (nucleotide reverse transcriptase inhibitors) and NNRTIs (non-nucleoside reverse transcriptase inhibitors) as HIV inhibitors, (iv) NtRTIs as HBV inhibitors and finally, (v) the transition of an HIV inhibitor to a stem cell mobilizer, as exemplified by AMD-3100 (Mozobil®).
Keywords
HIV; HBV; HSV; VSV; CMV; AIDS; ANPs; NRTIs; NtRTIs; NNRTIs
Subject
Medicine and Pharmacology, Epidemiology and Infectious Diseases
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment